C4 Therapeutics, Inc. (CCCC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

C4 Therapeutics, Inc. (CCCC) closed at USD 2.61 on 2026-10-14, a change of +1.2 % over the past year, with a market capitalization of USD 342.01M.

C4 Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

C4 Therapeutics, Inc. key figures

Previous close

USD 2.61 (2026-10-14)

1-year change

+1.2 %

Market cap

USD 342.01M

Enterprise value

USD 145.2M

P/E ratio (trailing)

-3.06

P/E ratio (forward)

-2.89

EPS (trailing)

-0.91

EPS (forward)

-0.96

PEG ratio

n/a

Price to book

1.38

Revenue growth

2.8 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

19.61

Employees

104

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About C4 Therapeutics, Inc.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for C4 Therapeutics, Inc. and compare it with other stocks.